Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance. MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth. MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression. Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.
11 December 2025 in Journal of Experimental & Clinical Cancer Research
Background: Neoadjuvant chemotherapy (NAT) is the standard treatment for osteosarcoma (OS), but patient responses vary, and conventional imaging or pathology offers limited predictive accuracy. Patient-derived organoids (PDOs) are promising models for assessing drug sensitivity and tumor viability ex vivo. This study evaluated the potential of PDO-based drug sensitivity testing and organoid formation potential (OFP) to predict therapeutic outcomes in OS. Methods: Tumor samples from OS patients collected before and after NAT were cultured as 3D PDOs. Chemosensitivity to first-line agents was quantified via a cell inhibition weighted score (CIWS), whereas OFP was used to reflect residual tumor viability. Clinical response was assessed via RECIST 1.1 and, for the primary analysis, dichotomized as responder (CR+PR+SD) versus nonresponder (PD); survival (OS/DFS) was tracked for up to 5 years. Correlations between PDO metrics and clinical outcomes were analyzed. Results: PDOs were established from 31 samples (18 pre-NAT samples and 13 post-NAT samples), including 8 paired pre/post-NAT samples. CIWS predicted NAT response assessed by RECIST 1.1 with 83.3% accuracy (pre-NAT, 15/18; 95% CI 58.6–96.4) and 5-year DFS with 84.6% accuracy (post-NAT, 11/13; 95% CI 54.6–98.1). With predefined CIWS/OFP cutoffs, Kaplan–Meier analyses showed longer DFS/OS in CIWS-sensitive and OFP-II/III (low growth) groups ( P <0.05). Conclusions: PDOs demonstrated promise as an ex vivo approach to evaluate whether ex vivo chemosensitivity and residual tumor viability measured by PDOs are associated with imaging response and 5-year survival. Their correlation with clinical outcomes highlights the potential of PDO testing to complement existing evaluation methods and to inform individualized treatment strategies.